Europe - Euronext Brussels - EBR:NYXH - BE0974358906 - Common Stock
The current stock price of NYXH.BR is 4.295 EUR. In the past month the price decreased by -5.71%. In the past year, price decreased by -44.08%.
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| 2M6.DE | MEDTRONIC PLC | 18.39 | 114.62B | ||
| 1MDT.MI | MEDTRONIC PLC | 18.68 | 114.29B | ||
| SHL.DE | SIEMENS HEALTHINEERS AG | 17.92 | 48.32B | ||
| PHI1.DE | KONINKLIJKE PHILIPS NV | 16.39 | 23.36B | ||
| PHIA.AS | KONINKLIJKE PHILIPS NV | 16.39 | 23.36B | ||
| 1PHIA.MI | KONINKLIJKE PHILIPS NV | 16.67 | 23.11B | ||
| BIM.PA | BIOMERIEUX | 27.95 | 12.77B | ||
| OBCK.DE | OTTOBOCK SE & CO KGAA | 157.02 | 4.72B | ||
| AFX.DE | CARL ZEISS MEDITEC AG - BR | 26.08 | 3.99B | ||
| DIA.MI | DIASORIN SPA | 18.66 | 3.46B | ||
| DRW3.DE | DRAEGERWERK AG - PREF | 10.93 | 1.32B | ||
| DRW8.DE | DRAEGERWERK AG | 9.64 | 1.17B |
Nyxoah SA is a medical technology company, which engages in the development and commercialization of solutions to treat Obstructive Sleep Apnea (OSA). The company is headquartered in Mont-Saint-Guibert, Brabant-Wallon and currently employs 184 full-time employees. The company went IPO on 2020-09-18. The firm focuses on the development and commercialization of solutions and services to treat sleep-disordered breathing conditions. The system consists of a neurostimulator, which is implanted close to the nerve of the tongue, as well as an activation chip, which is connected to a disposable patch and is positioned every night by the patient under the chin.
NYXOAH SA
Rue Edouard Belin 12
Mont-Saint-Guibert BRABANT-WALLON BE
Employees: 184
Phone: 3226121755
Nyxoah SA is a medical technology company, which engages in the development and commercialization of solutions to treat Obstructive Sleep Apnea (OSA). The company is headquartered in Mont-Saint-Guibert, Brabant-Wallon and currently employs 184 full-time employees. The company went IPO on 2020-09-18. The firm focuses on the development and commercialization of solutions and services to treat sleep-disordered breathing conditions. The system consists of a neurostimulator, which is implanted close to the nerve of the tongue, as well as an activation chip, which is connected to a disposable patch and is positioned every night by the patient under the chin.
The current stock price of NYXH.BR is 4.295 EUR. The price decreased by -0.92% in the last trading session.
NYXH.BR does not pay a dividend.
NYXH.BR has a ChartMill Technical rating of 1 out of 10 and a ChartMill Fundamental rating of 3 out of 10.
NYXOAH SA (NYXH.BR) currently has 184 employees.
NYXOAH SA (NYXH.BR) has a market capitalization of 160.76M EUR. This makes NYXH.BR a Micro Cap stock.
NYXOAH SA (NYXH.BR) will report earnings on 2026-03-11, after the market close.
ChartMill assigns a technical rating of 1 / 10 to NYXH.BR. When comparing the yearly performance of all stocks, NYXH.BR is a bad performer in the overall market: 95.1% of all stocks are doing better.
ChartMill assigns a fundamental rating of 3 / 10 to NYXH.BR. While NYXH.BR seems to be doing ok healthwise, there are quite some concerns on its profitability.
Over the last trailing twelve months NYXH.BR reported a non-GAAP Earnings per Share(EPS) of -2.24. The EPS decreased by -30.42% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -66.28% | ||
| ROE | -105.18% | ||
| Debt/Equity | 0.29 |
14 analysts have analysed NYXH.BR and the average price target is 12.19 EUR. This implies a price increase of 183.8% is expected in the next year compared to the current price of 4.295.
For the next year, analysts expect an EPS growth of -24.84% and a revenue growth 57.01% for NYXH.BR